Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Revenue of Spruce Biosciences, Inc. (SPRB)
Revenue in 2023 (TTM): $10.09 M
According to Spruce Biosciences, Inc.'s latest financial reports the company's current revenue (TTM) is $10.09 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Spruce Biosciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $10.09 M | $-39,343,000 | $-47,366,000 | $-47,919,000 | $-47,919,000 |
| 2022 | $ | $-429,000 | $-45,331,000 | $-46,180,000 | $-45,077,000 |
| 2021 | $ | $-381,000 | $-41,566,000 | $-42,292,000 | $-42,688,000 |
| 2020 | $ | $-102,000 | $-29,114,000 | $-29,539,000 | $-30,026,000 |
| 2019 | $ | $-12,000 | $-13,095,000 | $-13,088,000 | $-13,237,000 |
| 2018 | $ | $-1,000 | $-9,971,000 | $-9,858,000 | $-9,858,000 |